Drugs / Sarcoma-specific CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03356782 | Jun 2026 → Dec 2029 expected | Ewing sarcoma, bone sarcoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sarcoma-specific CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03356782 ↗ |
| Modality | Cell therapy | “CAR T cells immunotherapy” NCT03356782 ↗ |
| Route | Intravenous | “via IV” NCT03356782 ↗ |